Rafael Holdings, Inc. RFL
1.09 USD +0.02 (+1.87%)
At closeNov 11, 2026, 4:00 PM EST
1.11 +0.02 +1.83%
After hours · Nov 11, 4:00 PM ET
1.09 Day range 1.13
0.99 52-week range 3.96
- YTD
- -7.63%
- 1 year
- -14.17%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to…
benzinga.com Rafael Holdings Q4 EPS $(0.18) Up From $(0.28) YoY, Sales $244.000K Down From $350.000K YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.18) per share. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported…
benzinga.com Rafael Holdings Files New Drug Application To FDA For Approval Of Remibetadex To Treat Neurovisceral Manifestations Of Niemann-Pick Disease Type C Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking…